Group items tagged

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Woman to Woman, a program of the Ovarian Cancer Research Fund Alliance, pairs gynecologic cancer patients with trained survivor-volunteers who provide one-on-one emotional support and mentoring to women when they need it most. From the moment of diagnosis through the end of treatment, Woman to Woman survivor-volunteers have helped hundreds of women and their families cope with gynecologic cancer. Through the program, one-year grants of either $60,000 (for hospital-based programs) or $30,000 (for community-based organizations) will be awarded to institutions with a large volume of gynecologic cancer patients and a need to provide this type of support to patients. Grants are provided to cover the cost of a part-time program coordinator's salary (can be a new hire or a reassignment), program costs, and a patient fund (no indirect costs allowed). It is expected that each Woman to Woman program will become self-sustaining after the first year. OCRFA will provide all program materials for patients, as well as technical assistance and support, for the life of the program (even after the end of the grant period). Institutions and organizations also will have access to a dedicated section of the Woman to Woman website (under construction) featuring tools designed to assist them in the development and administration of new programs.

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.  

This Funding Opportunity Announcement (FOA) invites applications that seek to apply one or more innovative methodologies in communication research across the cancer control continuum, from prevention, early detection, diagnosis, treatment, and survivorship, to end of life. Applications to this FOA should utilize one or more of the following analytic approaches, methods, and data sources, including but not limited to social media data mining, Natural Language Processing (NLP) techniques, online social network analysis, crowdsourcing research tools (e.g., mTurk), online search data, Ecological Momentary Assessment, neuroscience and biobehavioral approaches to communication, and geographic information systems. Studies should assess outcomes related to cancer prevention and control (e.g., knowledge, attitudes, beliefs, perceived risk, decision making in screening and treatment, information inequalities, social support, shared decision making, persuasion, caregiving, behavioral intentions, preventive behaviors, and policy support, among others). This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research.

The Course Hero-Woodrow Wilson Fellowship for Excellence in Teaching will support rising stars in the academy who love teaching, demonstrate excellence as educators, and are making their mark as exceptional researchers, poised to shape their fields. Designed for young scholars working towards tenure, the Course Hero-WW Fellowship is a "genius grant" that will emphasize the balance between scholarly excellence and commitment to teaching practice that draws on new approaches to pedagogy, creating a new level of engagement for students in and beyond the classroom. In short, Fellows will be emerging heroes in their fields, on a clear trajectory to become great college educators. In its inaugural year, the Course Hero-WW Fellowship will identify five outstanding junior faculty members. Fellows will receive a one-year grant of $40,000-approximately $30,000 to support the engagement of a student assistant and the balance to be used for research and travel support. Exceptional candidates teach in ways that build student confidence and mastery of a subject; encourage critical thinking; explore foundational concepts through the lens of broader themes and global events; promote the power of learning communities beyond the classroom; leverage technology to complement the classroom experience; consider and serve different learning styles; prepare students for lifelong learning; and can serve as replicable teaching models for other educators. Selection takes place in June 2018. The five Fellows will be invited to attend the Course Hero Education Summit in July 2018, where their Fellowships will be announced.

The PFD Research Foundation together with the June Allyson Foundation has awarded over $1.5 million in grants to AUGS members since 1998. The Foundation serves the medical profession by supporting promising, innovative research regarding the causes, prevention, cure and treatment of pelvic floor disorders. Foundation research funds are made available to qualified AUGS members to pursue their research question. Goals of this research grant program are to support the completion of research projects which will lead to publication and presentation at future AUGS Annual Scientific Meetings and to support the development of researchers in the field who will go on to obtain additional funding for future research on pelvic floor disorders. Applicants can submit proposals for the following research awards: PFD Research Foundation Fellow Research Award: A two-year grant awarded to a fellow for clinical/patient-oriented, educational, or lab-based/basic science research. PFD Research Foundation Faculty Research Award: A two-year grant awarded to a junior faculty or affiliate member for clinical/patient-oriented, educational, or lab-based/basic science research. June Allyson Memorial Fund Research Award: A two-year grant awarded to a fellow for lab-based/basic science research. PFD Research Foundation and ICA IC/PBS Research Grant: A one-year grant awarded to a fellow, junior faculty or affiliate member of AUGS and ICA for research related to interstitial cystitis.

The primary purpose of this solicitation is to support highly interactive, multi-disciplinary teams, whose research efforts are focused on large-scale discovery of T cell immune epitopes associated with infectious or autoimmune diseases, and rejection of, or tolerance to, transplanted cells/organs/tissues. The discovery of epitopes associated with T cell responses to commensals and how they may be altered by the inflammatory state will also be supported by this solicitation. Validation of these epitopes and defining their role in immune protection or immune-mediated pathogenesis in humans is required. Investigators may include development/refinement of T cell epitope prediction tools as part of their research plan. It is anticipated that the multi-disciplinary teams will minimally include immunologists with the appropriate expertise in epitope identification and validation, and either microbiologists and/or virologists with expertise in the target pathogen(s), clinicians with expertise in the target autoimmune diseases, or clinicians with expertise in transplantation, as appropriate. This program will not support studies related to HIV/AIDS, or allergen epitopes, including those which are infection-related.

The FY18 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.

The FY20 LCRP Concept Award supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of lung cancer or develop an innovative and novel course of investigation. Submissions from and partnerships with investigators at Department of Defense (DoD) military treatment facilities and laboratories, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.

The purpose of the NIH Mentored Research Scientist Development Award (K01) is to provide support and protected time (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.

ENTELLIGENCE, in partnership with Actelion Pharmaceuticals US, supports basic science, translational, and clinical research in the field of cardiopulmonary medicine. The program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research in pulmonary hypertension. To that end, ENTELLIGENCE is accepting applications for its thirteenth annual Young Investigator grant program. Established in 2005, the program provides opportunities for promising young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, clinical, or translational) in the area of pulmonary hypertension specifically related to expanding knowledge of pulmonary vascular pathobiology pathways. In 2018, the program will award a one-year grant of up to $100,000 to fund a mentored project.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

The Jane Coffin Childs Memorial Fund for Medical Research was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes, and increasingly has focused its resources on the funding of three-year postdoctoral fellowships, supporting fellows selected by its board of scientific advisers from among the best young scientists at what is often a critical stage in their careers. As a result, there have been more than sixteen hundred Jane Coffin Childs fellows doing basic cancer-related research in laboratories in North America, Europe, Japan, and Australia. To advance its mission, the JCC Fund is accepting applications for its fellowship program. The fund supports between twenty-five and thirty new three-year cancer research fellowships every year. The current fellowship stipend levels are $52,000 for year one; $52,500 for year two; and $53,000 for year three.